TP53 and lip and oral cavity carcinoma: Collectively, these findings demonstrate that epithelial expression of the p53 GOF mutation p53R172H in 4NQO-induced oral lesions supports the development of an immune microenvironment that is refractory to reactivation by PD-1 inhibitors and promotes resistance to oral cancer immunoprevention.